DNA repair gene polymorphisms and risk of second primary neoplasms and mortality in oral cancer patients

Laryngoscope

Volumn 115, Issue 12, 2005, Pages 2221-2231

  Gal, Thomas J ^a   Huang, Wen Yi ^d   Chen, Chu ^a,b,c   Hayes, Richard B ^d   Schwartz, Stephen M ^b,c  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; DNA METHYLTRANSFERASE; GLUTAMINE; ISOLEUCINE; LEUCINE; LYSINE; METHIONINE; PHENYLALANINE; THREONINE; VALINE; DNA; POLYDEOXYRIBONUCLEOTIDE SYNTHASE;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER PATIENT; CANCER REGISTRY; CANCER RISK; CONTROLLED STUDY; DEMOGRAPHY; DNA POLYMORPHISM; DNA REPAIR; FEMALE; HUMAN; INTERVIEW; MALE; MOUTH CANCER; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; UPPER RESPIRATORY TRACT; XERODERMA PIGMENTOSUM; ADOLESCENT; ALLELE; COMPARATIVE STUDY; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; MIDDLE AGED; MORTALITY; MOUTH TUMOR; PATHOLOGY; RETROSPECTIVE STUDY; RISK FACTOR; SECOND CANCER; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE;

ADOLESCENT; ADULT; AGED; ALLELES; CARCINOMA, SQUAMOUS CELL; DNA REPAIR; DNA REPAIR ENZYMES; DNA, NEOPLASM; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MOUTH NEOPLASMS; NEOPLASMS, SECOND PRIMARY; POLYMORPHISM, GENETIC; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE;

EID: 33644803468     PISSN: 0023852X     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mlg.0000183736.96004.f7     Document Type: Article

References (64)

1. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer Statistics 2000. CA Cancer J 2000;50:7-33.
2. Blot WJ, McLaughlin JK, Devesa SS, Fraumeni JF. Cancers of the oral cavity and pharynx. In: Schottenfield DF, ed. Cancer epidemiology and prevention. New York: Oxford University, 1996:666-680.
3. Califano J, van der Riet P, Westra W, et al. Genetic progression model for head and neck cancer: implications for field cancerization. Cancer Res 1996;56:2488-92.
4. Hu JJ, Mohrenweiser HW, Bell DA, Miller MS. Symposium overview: genetic polymorphisms in DNA repair and cancer risk. Toxicol Appl Pharmacol 2002;185:64-73.
5. Yu Z, Chen J, Ford BN, et al. Human DNA repair systems: an overview. Environ Mol Mutagen 1999;33:3-20.
6. Berwick M, Vineis P. Markers of DNA repair and susceptibility to cancer in humans. J Natl Cancer Inst 2000;92:874-897.
7. Mohrenweiser HW, Jones IM. Variation in DNA repair is a factor in cancer susceptibility: a paradigm for the promises and perils of individual and population risk estimation. Mutat Res 1998;400:15-24.
8. Olshan AF, Watson MA, Weissler MC, Bell DA. XRCC1 polymorphisms and head and neck cancer. Cancer Lett 2002;178:181-186.
9. Coughlin SS, Khuri MJ, Steinberg KK. BRCA1 and BRCA2 gene mutations and the risk of breast cancer. Am J Prev Med 1999;16:91-98.
10. Crawford KW, Shields PG. Cancer susceptibility genes. In: Miller MS, Cronin MT, eds. Genetic polymorphisms and susceptibility to disease. New York: Taylor & Francis, 2000:89-107.
11. Caldecott KW, McKeown CK, Tucker JD, et al. An interaction between the mammalian DNA repair protein XRCC1 and DNA ligase III. Mol Cell Biol 1994;14:68-76.
12. Kubota Y, Nash RA, Klunglund A, et al. Reconstitution of DNA base excision-repair with purified human proteins: interaction between DNA polymerase beta and the XRCC1 protein. EMBO J 1996;15:6662-6670.
13. Sturgis EM, Castillo EJ, Lei L, et al. Polymorphisms of DNA repair gene XRCC1 in squamous cell carcinoma of the head and neck. Carcinogenesis 1999;20:2125-2129.
14. Liu N, Lamerdin JE, Tebbs RS. XRCC2 and XRCC3, new human Rad51-family members, promote chromosome stability and protect against DNA cross-links and other damages. Mol Cell Biol 1998;1:783-793.
15. Matullo G, Palli D, Peluso M, et al. XRCC1, XRCC3, XPD gene polymorphisms, smoking and 32P-DNA adducts in a sample of healthy subjects. Carcinogenesis 2001;22:1437-1445.
16. David-Beabes GL, Lunn RM, London SJ. No association between the XPD (Lys751Gln) polymorphism or the XRCC3 (Thr241Met) polymorphism and lung cancer risk. Cancer Epidemiol Biomark Prev 2001;10:911-912.
17. Butkiewicz D, Rusin M, Enewold L, et al. Genetic polymorphisms in DNA repair genes and risk of lung cancer. Carcinogenesis 2001;22:593-597.
18. Winsey SL, Halder NA, Marsh HP, et al. A variant within the DNA repair gene XRCC3 is associated with the development of melanoma skin cancer. Carcinogenesis 2000;60:5612-5616.
19. Shen H, Sturgis EM, Dahlstrom KR, et al. A variant of the DNA repair gene XRCC3 and risk of squamous cell carcinoma of the head and neck: a case control analysis. Int J Cancer 1999;99:869-872.
20. Flejter WL, McDaniell LD, Johns D, et al. Correction of xeroderma pigmentosum complementation group D mutant cell phenotypes by chromosome and gene transfer: involvement of the human ERCC2 DNA repair gene. Proc Natl Acad Sci 1992;89:261-265.
21. Braithwaite E, Wu X, Wang Z. Repair of DNA lesions and relative repair efficiencies. Mutat Res 1999;424:207-219.
22. de Last WL, Jaspers NG, Hoeijmakers JH. Molecular mechanism of nucleotide excision repair. Genes Dev 1999;13:768-785.
23. Sung P, Bailly VC, Thompson, LH, et al. Human xeroderma pigmentosum group D gene encodes a DNA helicase. Nature 1993;365:852-855.
24. Hoeijmakers JH, Egly JM, Vermeulen W. TFIIH: a key component in multiple DNA translation. Curr Opin Genet Dev 1996;6: 26-33.
25. Coin F, Marinoni JC, Rodolfo C, et al. Mutations in the XPD helicase gene result in XP and TTD phenotypes, preventing interaction between XPD and the p44 subunit of TFIIH. Nat Genet 1998;20:184-188.
26. Chen S, Tang D, Xue K, et al. DNA repair gene XRCC1 and XPD polymorphisms and risk of lung cancer in a Chinese population. Carcinogenesis 2002;23:1321-1325.
27. Hou SM, Falt S, Angelini S, et al. The XPD variant alleles are associated with increased DNA adduct levels and lung cancer risk. Carcinogenesis 2002;23:599-603.
28. Sturgis EM, Dahlstrom KR, Spitz MR, Wei Q. DNA repair gene ERCC1 and ERCC2/XPD polymorphisms and risk of squamous cell carcinoma of the head and neck. Arch Otolaryngol 2002;128:1084-1088.
29. Sturgis EM, Zheng R, Li L, et al. XPD/ERCC2 polymorphisms and risk of head and neck cancer: a case-control analysis. Carcinogenesis 2000;21:2219-2223.
30. Sturgis EM, Castillo EJ, Li L, et al. XPD/ERCC2 EXON 8 polymorphisms: rarity and lack of significance in risk of squamous cell carcinoma of the head and neck. Oral Oncol 2002;38:475-477.
31. Kaur T, Travaline JM, Gaughan JP, et al. Role of polymorphisms in codons 143 and 160 of the O6-Alkylguanine DNA alkyltranferase gene in lung cancer risk. Cancer Epidemiol Biomark Prev 2000;9:339-342.
32. Edara S, Kanugula S, Pegg AE. Expression of the inactive C145A mutant of O6-alkylguainine DNA alkyltransferase in E. coli increases cell killing and mutations by N-methyl-N-nitro-N-nitrosoguanidine. Carcinogenesis 1999;20:103-108.
33. Crone TM, Pegg AE. A single amino acid change in human O6-alkylguanine DNA alkyltranferase decreasing sensitivity to inactivation by O6-benzylguanine. Cancer Res 1993;53:4750-4753.
34. Matsukura S, Miyazaki K, Yakushiji H, et al. Expression and prognostic significance of O6-methylguanine-DNA methyltransferase in hepatocellular, gastric, and breast cancers. Ann Surg Oncol 2001;8:807-816.
35. Sanchez-Cespedes M, Esteller M, Wu L, et al. Gene promoter hypermethylation in tumors and serum of head and neck cancer patients. Cancer Res 2000;60:892-895.
36. Rosas SL, Koch W, da Costa Carvalho, MG, et al. Promoter hypermethylation patterns of p16, O6-methylguanine-DNA-methyltransferase, and death-associated protein kinase in tumors and saliva of head and neck cancer patients. Cancer Res 2001;61:939-942.
37. Khuri FR, Kim ES, Leem JJ, et al. The impact of smoking status, disease stage, and index tumor site on second primary tumor incidence and tumor recurrence in the head and neck retinoid chmoprevention trial. Cancer Epidemiol Biomark Prev 2001;10:823-829.
38. Vikram B. Changing patterns of failure in advanced head and neck cancer. Arch Otolaryngol 1984;110:564-565.
39. van Oijen MG, Leppers vd Straat FG, Tilanus MG, Slootweg PJ. The origins of multiple squamous cell carcinomas in the aerodigestive tract. Cancer 2000;88:884-893.
40. Hattori K, Inohara H, Sawada T, et al. Association of p53 expression with second primary tumour development in hypopharyngeal carcinoma. J Laryngol Otol 2000;114:198-201.
41. Cianfriglia F, DI Gregorio DA, Manieri A. Multiple primary tumours in patients with oral squamous cell carcinoma. Oral Oncol 1999;35:157-163.
42. Maden C, Beckmann AM, Thomas DB, et al. Human papillomavirus, herpes simplex virus, and the risk of oral cancer in men. Am J Epidemiol 1992;90:1093-1102.
43. Schwartz SM, Daling JR, Doody DR, et al. Oral cancer risk in relation to sexual history and evidence of human papilomavirus. J Natl Cancer Inst 1998;90:1626-1636.
44. Percy C, van Holten V, Muir C. International classification of diseases for oncology, 2nd ed. Geneva, Switzerland: World Health Organization, 1990.
45. Bray M, Boerwinkle E, Doris PA. High-throughput multiplex SNP genotyping with MALDI-TOF mass spectrometry: practice, problems, and promise. Hum Mutat 2001;17:296-304.
46. Cox DR. Regression models and life tables. J Roy Stat Soc 1972;34(B):187-220.
47. Kleinbaum DG. Survival analysis. New York: Springer-Verlag, 1996.
48. Rafferty MA, O'Dwyer, TP. Second primary malignancies in head and neck squamous cell carcinoma. J Laryngol Otol 2001;115:988-991.
49. Holland JM, Arsanjani A, Liem BJ, et al. Second malignancies in early stage laryngeal carcinoma patients treated with radiotherapy. J Laryngol Otol 2002;116:190-193.
50. Slaughter DP, Southwick HW, Smejkal W. Field cancerization in oral stratified squamous epithelium. Cancer 1953;6:963-968.
51. Monique GCT, Oijen V, Slootweg PJ. Oral field cancerization: carcinogen-induced independent events or micrometastatic deposits? Cancer Epidemiol Biomark & Prev 2000;9:249-256.
52. Partridge M, Emilion G, Pateromichalakis S, et al. Field cancerization of the oral cavity: comparison of the spectrum of molecular alterations in cases presenting with both dysplastic and malignant lesions. Oral Oncol 1997;33:332-337.
53. Bedi GC, Westra W, Gabrielson E, et al. Multiple head and neck tumors: evidence for a common clonal origin. Cancer Res 1996;56:2484-2487.
54. Carey T. Field cancerization: are multiple primaries monoclonal or polyclonal? Ann Med 1996;28:183-188.
55. Spitz MR, Hoque A, Trizna Z, et al. Mutagen sensitivity as a risk factor for second malignant tumors following malignancies of the upper aerodigestive tract. J Natl Cancer Inst 1994;86:1681-1674.
56. Matullo G, Guarrera S, Carturan S, et al. DNA repair gene polymorphisms, bulky DNA adducts in white blood cells and bladder cancer in a case-control study. Int J Cancer 2001;94:562-567.
57. Goode EL, Ulrich CM, Potter JD. Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomark Prev 2002;11:1513-1530.
58. David-Beabes GL, London SJ. Genetic polymorphism of XRCC1 and lung cancer risk among African-Americans and Caucasians. Lung Cancer 2001;34:333-339.
59. Divine KK, Gilliland FD, Crowell RE, et al. The XRCC1 399 glutamine allele is a risk factor for adenocarcinoma of the lung. Mutat Res 2001;461:273-278.
60. Ratnasinghe D, Yao SX, Tangrea JA, et al. Polymorphisms of the DNA repair gene XRCC1 and lung cancer risk. Cancer Epidemiol Biomark Prev 2001;10:119-123.
61. Huang WY, Olshan AF, Schwartz SM, et al. Selected genetic polymorphisms in MGMT, XRCC1, XPD, and XRCC3 and risk of head and neck cancer: a pooled analysis. Cancer Epidemiol Biomark Preve 2005;14:1823-1827.
62. Geisler SA, Afil O, Cai, JW, et al. Glutathione S-transferase polymorphisms and survival from head and neck cancer. Head Neck 2005;27:232-242.
63. Spector JG, Sessions DG, Haughey BH, et al. Delayed regional metastases, distant metastases, and second primary malignancies in squamous cell carcinomas of the larynx and hypopharynx. Laryngoscope 2001;111:1079-1087.
64. Yamamoto E, Shibuya H, Yoshimura R, Miura M. Site specific dependency of second primary cancer in early stage head and neck squamous cell carcinoma. Cancer 2002;94:2007-2014.